NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
University of California, Davis
M.D. Anderson Cancer Center
Hospital das ClÃnicas de Ribeirão Preto
University of Wisconsin, Madison
Masonic Cancer Center, University of Minnesota
H. Lee Moffitt Cancer Center and Research Institute